JPH039882B2 - - Google Patents
Info
- Publication number
- JPH039882B2 JPH039882B2 JP57133073A JP13307382A JPH039882B2 JP H039882 B2 JPH039882 B2 JP H039882B2 JP 57133073 A JP57133073 A JP 57133073A JP 13307382 A JP13307382 A JP 13307382A JP H039882 B2 JPH039882 B2 JP H039882B2
- Authority
- JP
- Japan
- Prior art keywords
- ifn
- active substance
- mice
- cells
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000004480 active ingredient Substances 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 239000002799 interferon inducing agent Substances 0.000 claims description 2
- 239000013543 active substance Substances 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 241000700618 Vaccinia virus Species 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 241000700647 Variola virus Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000013040 bath agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57133073A JPS5925329A (ja) | 1982-07-30 | 1982-07-30 | インタ−フエロン誘起剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57133073A JPS5925329A (ja) | 1982-07-30 | 1982-07-30 | インタ−フエロン誘起剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5925329A JPS5925329A (ja) | 1984-02-09 |
| JPH039882B2 true JPH039882B2 (fr) | 1991-02-12 |
Family
ID=15096209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57133073A Granted JPS5925329A (ja) | 1982-07-30 | 1982-07-30 | インタ−フエロン誘起剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5925329A (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0797467B2 (ja) * | 1984-12-20 | 1995-10-18 | 三菱電機株式会社 | 接地タンク形ガスしや断器 |
| IE61758B1 (en) * | 1986-05-23 | 1994-11-30 | Daiichi Seiyaku Co | Use of a sulfated polysaccharide |
-
1982
- 1982-07-30 JP JP57133073A patent/JPS5925329A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5925329A (ja) | 1984-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69333321T2 (de) | Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten. | |
| JP2000507917A (ja) | 持続的低用量サイトカイン注入治療 | |
| Kleinschmidt et al. | Interferon induction with statolon in the intact animal | |
| STRINGFELLOW et al. | Interferon induction by 5-halo-6-phenyl pyrimidinones | |
| Kremsner et al. | Interferon‐γ induced lethality in the late phase of Plasmodium vinckei malaria despite effective parasite clearance by chloroquine | |
| Stringfellow | Comparation interferon-inducing and antiviral properties of 2-amino-5-bromo-6-methyl-4-pyrimidinol (U-25,166), tilorone hydrochloride, and polyinosinic-polycytidylic acid | |
| JP3496937B2 (ja) | コンセンサスヒトインターフェロンを含有する細胞増殖障害治療用の医用組成物 | |
| RU2730998C2 (ru) | Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении | |
| Brunda et al. | The anti‐tumor effect of recombinant interferon alpha or gamma is influenced by tumor location | |
| Ohno | Interferons in the treatment of multiple myeloma | |
| KISHIMOTO et al. | Prevention of murine coxsackie B3 viral myocarditis and associated lymphoid organ atrophy with recombinant human leucocyte interferon αA/D | |
| JPH039882B2 (fr) | ||
| Lucia et al. | Arenavirus infection in the guinea pig model: Antiviral therapy with recombinant interferon-α, the immunomodulator CL246, 738 and ribavirin | |
| KR20070012522A (ko) | 면역조절제 화합물로의 호흡기 바이러스 감염의 치료 및예방 | |
| Papamatheakis et al. | Cell and Tissue Distribution of ¹¹C-Labeled Pyran Copolymer | |
| JPS58170715A (ja) | インタ−フエロンの誘起剤 | |
| EP3912627B1 (fr) | Procédés de traitement des infections par coronavirus | |
| CA1336491C (fr) | Composition pharmaceutique ayant une action antivirale | |
| KAMIN-LEWIS et al. | Decreased interferon synthesis and responsiveness to interferon by leukocytes from multiple sclerosis patients given natural alpha interferon | |
| Papayannopoulou et al. | Tissue isozyme alterations in cyanate treated animals | |
| KR100364938B1 (ko) | 만성 씨형 간염의 치료를 위한 인테페론-알파와 아만타딘을 함유한 약제 | |
| JPH08503001A (ja) | 免疫組織および免疫反応強化化合物 | |
| US20040142882A1 (en) | Use of glycyrrhizin and its derivatives as RANTES inducers | |
| Finkelstein et al. | Interferon--1968. How much do we understand? | |
| US4486407A (en) | Method for enhancing production of interferon |